Nucleoside reverse transcriptase inhibition enhances platelet production and megakaryocyte maturation in patients with COVID ‐19
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20006 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Yubin Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Megakaryocytes, COVID-19 Drug Treatment, Blood Platelets, Reverse Transcriptase Inhibitors. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Major Fundamental Research Project of Shandong Province, Excellent Young Scientists Fund, Distinguished Young and Middle-aged Scholar Foundation of Shandong University.
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID‐19) is a systemic infection frequently involving the haematopoietic system. Thrombocytopenia is associated with increased risks of severe disease progression and mortality. Antiviral agents have shown much promise in decreasing viral load and shortening the time to the resolution of symptoms. However, their effect on platelet counts in patients with COVID‐19 remains unexplored. Therefore, we first performed a retrospective study to evaluate the variation in platelet mass of hospitalized patients with high‐risk COVID‐19 who were given either SARS‐CoV‐2 main protease inhibitor, nucleoside reverse transcriptase inhibitor or no antiviral agents. A total of 177 patients were included, among which 64 received azvudine, 12 received nirmatrelvir–ritonavir and 101 patients received none. Compared to those without antiviral treatment, significantly higher platelet counts' increments were observed in patients receiving azvudine or nirmatrelvir–ritonavir ( p = 0.001). Of note, this elevation was significantly more profound in the azvudine group than that in the control group ( p < 0.001) or the nirmatrelvir–ritonavir group ( p = 0.042). Subsequently, in vitro experiments were conducted to investigate the mechanism of platelet elevation underlying the activity of azvudine. Results showed that azvudine promoted the polyploidization and platelet production of the MEG‐01 cell line. Although azvudine had minimal effect on megakaryopoiesis, it could significantly trigger platelet release of megakaryocytes in the presence of SARS‐CoV‐2 spike‐membrane recombinant fusion protein or not. Finally, RNA‐sequencing demonstrated that azvudine‐treated MEG‐01 exhibited a marked increase in VWF , TUBB1 and GP1BA , and upregulated genes associated with the PI3K/AKT and JAK/STAT signalling pathways. In conclusion, our findings indicated that nucleoside reverse transcriptase inhibition potentially enhances platelet production and megakaryocyte maturation in patients with COVID‐19, suggesting a new therapeutic option for thrombocytopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong, China.
- Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, China.
ORCID-Profile: Yu Hou
Förderung
- Major Fundamental Research Project of Shandong Province
- Excellent Young Scientists Fund
- Distinguished Young and Middle-aged Scholar Foundation of Shandong University
- National Natural Science Foundation of China
- Young Taishan Scholar Foundation of Shandong Province
- Major Research and Development Plan of Shandong Province
- Clinical Research Center of Shandong University
Zitieren
APA
Li, Y., Wang, J., Huang, B., Wang, R., Xu, Y., Zhang, P., Wang, R., Wang, W., Cao, J., Hou, M., & Hou, Y. (2025). Nucleoside reverse transcriptase inhibition enhances platelet production and megakaryocyte maturation in patients with COVID ‐19. British Journal of Haematology. https://doi.org/10.1111/bjh.20006
Vancouver
Li Y, Wang J, Huang B, Wang R, Xu Y, Zhang P, et al. Nucleoside reverse transcriptase inhibition enhances platelet production and megakaryocyte maturation in patients with COVID ‐19. British Journal of Haematology. 2025. doi:10.1111/bjh.20006
BibTeX
@article{Li2025,
author = {Li, Yubin and Wang, Juan and Huang, Bingqian and Wang, Ruixue and Xu, Yitong and Zhang, Ping and Wang, Ruting and Wang, Wanru and Cao, Junying and Hou, Ming and Hou, Yu},
title = {Nucleoside reverse transcriptase inhibition enhances platelet production and megakaryocyte maturation in patients with COVID ‐19},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20006}
}
EUVIMED